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FM Journal Club Bottom Line: Beta-blocker use and clinical outcomes in stable 
outpatients with and without coronary artery disease 
 
Clinical question: Which patients should be placed/kept on beta-blocker therapy?  
 
Bottom line answer:  
 Randomized control trials show beta-blockers benefit patients with systolic 
congestive heart failure and for the first three years after a patient has a MI. 
 Beta-blocker use may not be associated with lower event rates of CV death, 
non-fatal MI, stroke of hospitalization in patients even with prior history of 
MI after 3 years.  
 Level 2b evidence: Recent longitudinal study followed 3 cohorts of 
patients for 44 months with and without beta-blocker use: 1) prior MI  
2) CAD no prior MI  3) risk factors for CAD only.   
 There were no significant differences in primary outcomes of 
cardiovascular death, non-fatal MI or non-fatal stroke in the 
known MI or CAD without prior MI cohorts 
 In patients with no known CAD history (only risk factors), 
betablocker use may be associated with increased risk of CV 
death, non-fatal MI and stroke (HR 1.18, p = 0.02) 
 Secondary outcomes of hospitalization for atheroembolic event 
and revascularization procedures were increased in patients 
using beta-blockers who had known CAD but no prior MI and 
CAD risk factors only.   
 Results were not specified for type or dose of betablocker  
 
Case: 62 year old man who is 5 yrs s/p stent for known MI presents wanting to 
minimize his medications.  Currently taking statin, asa, betablocker, ACEI, 
metformin.  BP 116/72  HgA1c  6.4.  Should he stop his betablocker?  
 
Background and supporting evidence:  
 AHA 2011 guidelines now recommend betablocker therapy for heart failure 
patients and MI or ACS patient for 3 years after MI (as class I 
recommendation)  
 AHA guidelines recently changed its recommendation for longterm 
betablocker therapy from  class IIa to class IIb 
 European Society of Cardiology now recommends longterm betablocker 
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